About this Information
This section provides supporting information for the Dupixent Dose Calculator. It outlines the tool's parameters, explains its outputs, and offers a general overview of Dupixent (dupilumab) dosing based on the U.S. Prescribing Information. Always consult a licensed healthcare professional and the full prescribing information before making any clinical decisions.
Outputs
After entering the required patient information, the calculator will provide the following outputs based on the selected indication:
- Recommended Dosing Regimen: Specifies the approved dose and frequency.
- Initial (Loading) Dose: The starting dose, which is often higher than subsequent doses to rapidly achieve therapeutic levels.
- Maintenance Dose: The ongoing dose administered at regular intervals after the initial dose.
- Dosing Rationale: A brief explanation of why a specific regimen is recommended for the patient's profile (e.g., age, weight, and indication).
How to Use
To determine the appropriate dosing schedule, follow these steps in the calculator above:
- Select Indication: Choose the condition for which Dupixent is being prescribed from the dropdown menu.
- Enter Patient Age: Input the patient's age in years. For infants, use decimals (e.g., 0.5 for 6 months).
- Enter Patient Weight: Input the patient's body weight. This field is only required for specific indications where dosing is weight-dependent (e.g., Atopic Dermatitis, Asthma, and Eosinophilic Esophagitis). You can toggle between kilograms (kg) and pounds (lbs).
- Calculate: Click the "Calculate Dose" button to view the recommended regimen.
Dosing Overview
Dupixent is administered as a subcutaneous injection. Dosing regimens are highly specific and vary based on the patient's indication, age, and, in many cases, body weight. Some indications require an initial loading dose, followed by smaller maintenance doses. For example, adults with atopic dermatitis typically receive a 600 mg loading dose, followed by 300 mg every two weeks. In contrast, adults with CRSwNP receive 300 mg every two weeks without a loading dose. Pediatric dosing is further stratified by specific age and weight brackets, highlighting the importance of accurate patient data for correct dose determination.
Switching
Switching a patient from another biologic agent to Dupixent, or vice versa, is a clinical decision that requires careful consideration by the treating physician. Factors such as the patient's disease activity, prior treatment response, and the pharmacokinetic properties of the drugs involved must be evaluated. There is no universally standardized protocol, and decisions should be individualized.
Missed Dose
If a dose of Dupixent is missed, the patient should be instructed to administer the injection as soon as possible and then resume their regular dosing schedule. For a weekly dosing schedule, the next dose can be administered as soon as possible, and the weekly schedule resumes from that date. For a schedule of every 2 or 4 weeks, if a dose is missed, administer the injection within 7 days of the missed dose, then resume the original schedule. If more than 7 days have passed, the patient should wait for the next scheduled dose. Patients should always consult their healthcare provider for specific instructions.
Safety Alerts
Frequently Asked Questions
Does the calculator require weight for all indications?
No. For adults (18 years and older), weight is not required to calculate the dose for Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) or Prurigo Nodularis (PN). However, weight is a critical parameter for Atopic Dermatitis, Asthma, and Eosinophilic Esophagitis across various age groups.
What happens if I enter an age below the approved indication?
The calculator will display an error message. For example, if you enter an age of 5 for Asthma (indicated for ages 6 and up), the tool will state that Dupixent is not indicated for that patient profile, reflecting the guidelines in the prescribing information.
What is a "loading dose"?
A loading dose is a higher initial dose of a drug given at the beginning of a course of treatment before dropping down to a lower maintenance dose. It is used to quickly achieve the therapeutic concentration of the drug in the body. Several Dupixent indications, such as Atopic Dermatitis and Prurigo Nodularis, require a loading dose.
How is Dupixent administered?
Dupixent is administered via subcutaneous (under the skin) injection. It is available in a pre-filled syringe or a pre-filled pen for self-administration after proper training from a healthcare professional.
Why is the dosing for Eosinophilic Esophagitis (EoE) weekly for some patients?
For patients aged 12 years and older weighing at least 40 kg, the FDA-approved dose for EoE is 300 mg administered weekly. This higher frequency regimen was established in clinical trials to be effective for this specific patient population.
Does the maintenance dose for pediatric asthma require a loading dose?
No. According to the U.S. Prescribing Information, the add-on maintenance treatment for asthma in patients aged 6 to 11 years does not require an initial loading dose. The maintenance dose is given every two or four weeks, depending on body weight.
Can this calculator be used for patients outside the United States?
This calculator is based specifically on the U.S. FDA Prescribing Information (Revised: 01/2024). Dosing recommendations and approved indications may differ in other countries or regions. Always consult local regulatory guidelines (e.g., from the EMA in Europe) for non-U.S. patients.
Where can I find the official prescribing information referenced by the tool?
The tool and this content are based on the official U.S. FDA label for Dupixent. A link to the most current version is provided in the references section below and at the bottom of the calculator tool.
References
- DUPIXENT® (dupilumab) injection, for subcutaneous use. U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. January 2024. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761055s038lbl.pdf
- Sanofi & Regeneron. DUPIXENT® HCP Official Site. Accessed October 2023. Available from: https://www.dupixenthcp.com/
- European Medicines Agency (EMA). Dupixent (dupilumab) Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent
- Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130-139. doi:10.1056/NEJMoa1314768. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa1314768
